Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE)
- 27 November 2016
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 116 (12), 1172-1179
- https://doi.org/10.1160/th16-04-0335
Abstract
Venous thromboembolism (VTE) is a common disorder associated with significant rates of morbidity and mortality. VTE management aims to reduce mortality, the risks of recurrence, and long-term complications. VTE treatment is evolving with the introduction of non-vitamin K antagonist anticoagulants (NOACs). The Global Anticoagulant Registry in the FIELD – Venous Thromboembolism (GARFIELD-VTE) is a prospective, multicentre, observational study that will enrol 10,000 patients treated for acute VTE from ∼500 sites in 28 countries. Identified sites reflect the diversity of care settings, including hospital and outpatient settings. Patients will be managed according to local practices and followed for at least three years. The primary objective is to determine the extent to which VTE treatment varies in the real-world setting and to assess the impact of such variability on clinical and economic outcomes. Evolving patterns of care will be captured using two sequential cohorts. The GARFIELD-VTE registry will provide insights into the evolving global treatment patterns for VTE, both deep-vein thrombosis and pulmonary embolism. By enrolling patients from diverse care settings, the registry will provide information on adherence to national and international guidelines, identify good practice as well as treatment deficiencies, and relate patient outcomes to clinical management. The incidence of death, recurrent VTE, bleeding, post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension will be documented. By capturing information during and after anticoagulation treatment, the registry will not only define aspects of the natural history of VTE, but also its economic and societal impact at a regional and global level.Keywords
Funding Information
- Thrombosis Research Institute
This publication has 35 references indexed in Scilit:
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patientsHealth and Quality of Life Outcomes, 2012
- Risk factors for post‐thrombotic syndrome in patients with a first deep venous thrombosisJournal of Thrombosis and Haemostasis, 2008
- Patient Outcomes After Deep Vein Thrombosis and Pulmonary EmbolismThe Worcester Venous Thromboembolism StudyArchives of Internal Medicine, 2008
- Venous thromboembolism (VTE) in EuropeThrombosis and Haemostasis, 2007
- Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndromeAmerican Journal of Health-System Pharmacy, 2006
- Venous thromboembolism: disease burden, outcomes and risk factorsJournal of Thrombosis and Haemostasis, 2005
- Predictors of the post‐thrombotic syndrome during long‐term treatment of proximal deep vein thrombosisJournal of Thrombosis and Haemostasis, 2005
- Post-thrombotic syndrome, functional disability and quality of life after upper extremity deep venous thrombosis in adultsThrombosis and Haemostasis, 2005